Chronic kidney disease: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
imported>Robert Badgett
Line 63: Line 63:
* Vitamin D preparations such as [[calcitriol]] (0.25-0.5 µg orally once per day) or intravenous paricalcitol (Zemplar<sup>™</sup>)are given once a patient has Stage 3 disease in order to prevent secondary [[hyperparathyroidism]].
* Vitamin D preparations such as [[calcitriol]] (0.25-0.5 µg orally once per day) or intravenous paricalcitol (Zemplar<sup>™</sup>)are given once a patient has Stage 3 disease in order to prevent secondary [[hyperparathyroidism]].
* Calcimimetic such as [[cinacalcet]] (Sensipar<sup>™</sup>) may help.
* Calcimimetic such as [[cinacalcet]] (Sensipar<sup>™</sup>) may help.
If hypercalcemia develops, guidelines are available for management.ref name="pmid14520607b">{{cite journal| author=National Kidney Foundation| title=K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. | journal=Am J Kidney Dis | year= 2003 | volume= 42 | issue= 4 Suppl 3 | pages= S1-201 | pmid=14520607 | url=http://www.kidney.org/professionals/KDOQI/guidelines_bone/index.htm }} (see [http://www.kidney.org/professionals/KDOQI/guidelines_bone/guidestate.htm recommendations])</ref>


====Allopurinol====
====Allopurinol====

Revision as of 07:27, 11 October 2010

This article is a stub and thus not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Chronic_kidney_disease&printable=yes
This editable Main Article is under development and subject to a disclaimer.

In medicine, chronic kidney disease (CKD) is defined as "kidney damage or glomerular filtration rate (GFR) <60 mL/min/1.73 m(2) for 3 months or more, irrespective of cause. Kidney damage in many kidney diseases can be ascertained by the presence of albuminuria, defined as albumin-to-creatinine ratio >30 mg/g in two of three spot urine specimens."[1]

Classification

There are five stages:[1]

Etiology/cause

Bilateral renal artery stenosis (RAS) may cause 5% to 15% of cases of chronic kidney disease.[2]

Prevalence

Thirteen percent of adults in the United States of America have chronic kidney disease as defined by the Kidney Disease Outcomes Quality Initiative (KDOQI).[3] The prevalence is reduced to 11% if isolated microalbuminuria (CKD-1) is not included.[3] However, using otehr criteria, the prevalence is 2.9%.[4]

Routine reporting of the estimated glomerular filtration rate has increased the number of referrals to nephrologists[5]; however, the benefit is uncertain[6].

Signs and symptoms

Uremia, "the illness accompanying kidney failure", may have subtle manifestations when the glomerular filtration rate falls below 60 ml/min/1.73 m2.[7]

Anemia of chronic disease commonly coexists with CKD.

Treatment

The National Kidney Disease Education Program provides guidance on dosing drugs in patients with reduced glomerular filtration rate.[8]

Various drugs have been studied for slowing the progression of chronic kidney disease.[9][10][11]

Systematic reviews by the Cochrane Collaboration on treatments for chronic kidney disease
Treatment Setting Results
Protein restriction[9] Diabetic renal disease relative risk of end stage renal disease or death:
0.23
Protein restriction[10] Non-diabetic renal disease relative risk of renal death:
0.69
Angiotensin converting enzyme inhibitors[11] Diabetic renal disease  

Medications

Aldosterone antagonists

Aldosterone antagonists may reduce proteinuria according to a systematic review by the Cochrane Collaboration.[12]

Angiotensin inhibition

Angiotensin can be inhibited with either angiotensin-converting enzyme inhibitors[13] or angiotensin II receptor antagonists. These medications can help patients with an elevated creatinine,[14] including those with a creatinine of 1.5 to 5.0 mg per deciliter.[15]

Combining angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists increases effect, but at uncertain increase in drug toxicity such as hyperkalemia according to a meta-analysis.[16] Adding an aldosterone receptor antagonist such as spironolactone may add further benefit, but presumably more hyperkalemia.[17]

Erythropoeitin

For more information, see: Erythropoeitin.


Secondary hyperparathyroidism

Clinical practice guidelines from the "Kidney Disease: Improving Global Outcomes (KDIGO)" address management of renal osteodystrophy.[18][19]

  • Phosphate binders (calcium carbonate 650 mg tabs three times - Calcichew™, Titrala™) or calcium acetate (Phosex™, PhosLo™) per day by mouth.
  • Vitamin D preparations such as calcitriol (0.25-0.5 µg orally once per day) or intravenous paricalcitol (Zemplar™)are given once a patient has Stage 3 disease in order to prevent secondary hyperparathyroidism.
  • Calcimimetic such as cinacalcet (Sensipar™) may help.

If hypercalcemia develops, guidelines are available for management.ref name="pmid14520607b">National Kidney Foundation (2003). "K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.". Am J Kidney Dis 42 (4 Suppl 3): S1-201. PMID 14520607. 

(see recommendations)</ref>

Allopurinol

A single randomized controlled trial found that giving allopurinol to hyperuricemic patients with chronic kidney disease had a relative risk ratio of 0.35 in the prevention of "significant deterioration in renal function and dialysis dependence."[20]

Treatment of associated diseases

Coronary heart disease

Coronary heart disease is common among patients with chronic kidney disease.

Hypertension

Renal replacement therapy

For more information, see: Renal replacement therapy.


Prognosis

The estimated glomerular filtration rate and the urinary albumin/creatinine ratio can help predict who will progress to CKD5.[22]

References

  1. ↑ 1.0 1.1 Levey AS, Eckardt KU, Tsukamoto Y, et al (2005). "Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)". Kidney Int. 67 (6): 2089–100. DOI:10.1111/j.1523-1755.2005.00365.x. PMID 15882252. Research Blogging.
  2. ↑ Rimmer JM, Gennari FJ (May 1993). "Atherosclerotic renovascular disease and progressive renal failure". Ann. Intern. Med. 118 (9): 712–9. PMID 8460859. [e]
  3. ↑ 3.0 3.1 Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P et al. (2007). "Prevalence of chronic kidney disease in the United States.". JAMA 298 (17): 2038-47. DOI:10.1001/jama.298.17.2038. PMID 17986697. Research Blogging.
  4. ↑ Rutkowski M, Mann W, Derose S, Selevan D, Pascual N, Diesto J et al. (2009). "Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente.". Am J Kidney Dis 53 (3 Suppl 3): S86-99. DOI:10.1053/j.ajkd.2008.07.052. PMID 19231766. Research Blogging.
  5. ↑ Hemmelgarn BR, Zhang J, Manns BJ, James MT, Quinn RR, Ravani P et al. (2010). "Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate.". JAMA 303 (12): 1151-8. DOI:10.1001/jama.2010.303. PMID 20332400. Research Blogging.
  6. ↑ den Hartog JR, Reese PP, Cizman B, Feldman HI (2009). "The costs and benefits of automatic estimated glomerular filtration rate reporting.". Clin J Am Soc Nephrol 4 (2): 419-27. DOI:10.2215/CJN.04080808. PMID 19176794. PMC PMC2637597. Research Blogging.
  7. ↑ Meyer TW, Hostetter TH (2007). "Uremia.". N Engl J Med 357 (13): 1316-25. DOI:10.1056/NEJMra071313. PMID 17898101. Research Blogging.
  8. ↑ The National Kidney Disease Education Program. (2009) Chronic Kidney Disease and Drug Dosing: Information for Providers National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), U.S. Department of Health & Human Services (DHHS).
  9. ↑ 9.0 9.1 Robertson L, Waugh N, Robertson A (2007). "Protein restriction for diabetic renal disease". Cochrane Database Syst Rev (4): CD002181. DOI:10.1002/14651858.CD002181.pub2. PMID 17943769. Research Blogging.
  10. ↑ 10.0 10.1 Fouque D, Laville M, Boissel JP (2006). "Low protein diets for chronic kidney disease in non diabetic adults". Cochrane Database Syst Rev (2): CD001892. DOI:10.1002/14651858.CD001892.pub2. PMID 16625550. Research Blogging.
  11. ↑ 11.0 11.1 Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC (2006). "Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease". Cochrane Database Syst Rev (4): CD006257. DOI:10.1002/14651858.CD006257. PMID 17054288. Research Blogging.
  12. ↑ Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF (2009). "Aldosterone antagonists for preventing the progression of chronic kidney disease.". Cochrane Database Syst Rev (3): CD007004. DOI:10.1002/14651858.CD007004.pub2. PMID 19588415. Research Blogging.
  13. ↑ Jafar TH, Stark PC, Schmid CH, et al (2003). "Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis". Ann. Intern. Med. 139 (4): 244–52. PMID 12965979. [e]
  14. ↑ Ruggenenti P, Perna A, Remuzzi G (2001). "ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy". J. Am. Soc. Nephrol. 12 (12): 2832–7. PMID 11729254. [e]
  15. ↑ Hou FF, Zhang X, Zhang GH, et al (2006). "Efficacy and safety of benazepril for advanced chronic renal insufficiency". N. Engl. J. Med. 354 (2): 131–40. DOI:10.1056/NEJMoa053107. PMID 16407508. Research Blogging.
  16. ↑ Kunz R, Friedrich C, Wolbers M, Mann JF (January 2008). "Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease". Ann. Intern. Med. 148 (1): 30–48. PMID 17984482. [e]
  17. ↑ Tylicki L, Rutkowski P, Renke M, et al (September 2008). "Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial". Am. J. Kidney Dis. 52 (3): 486–93. DOI:10.1053/j.ajkd.2008.02.297. PMID 18423812. Research Blogging.
  18. ↑ Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K et al. (2006). "Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).". Kidney Int 69 (11): 1945-53. DOI:10.1038/sj.ki.5000414. PMID 16641930. Research Blogging. Free full text
  19. ↑ National Kidney Foundation (2003). "K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.". Am J Kidney Dis 42 (4 Suppl 3): S1-201. PMID 14520607.
  20. ↑ Siu YP, Leung KT, Tong MK, Kwan TH (January 2006). "Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level". Am. J. Kidney Dis. 47 (1): 51–9. DOI:10.1053/j.ajkd.2005.10.006. PMID 16377385. Research Blogging.
  21. ↑ Appel LJ, Wright JT, Greene T, Agodoa LY, Astor BC, Bakris GL et al. (2010). "Intensive blood-pressure control in hypertensive chronic kidney disease.". N Engl J Med 363 (10): 918-29. DOI:10.1056/NEJMoa0910975. PMID 20818902. Research Blogging.
  22. ↑ Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR (April 2009). "Combining GFR and Albuminuria to Classify CKD Improves Prediction of ESRD". J. Am. Soc. Nephrol.. DOI:10.1681/ASN.2008070730. PMID 19357254. Research Blogging.

External links

Retrieved from "https://citizendium.org/wiki/index.php?title=Chronic_kidney_disease&oldid=311145"